Thalidomide for the treatment of AIDS-associated wasting

AIDS Research and Human Retroviruses

Volumn 16, Issue 14, 2000, Pages 1345-1355

  Kaplan, G ^a   Thomas, S ^b   Fierer, D S ^c   Mulligan, K ^d   Haslett, P A J ^a   Fessel, W J ^e   Smith, L G ^f   Kook, K A ^c   Stirling, D ^b   Schambelan, M ^d  

^a ROCKEFELLER UNIVERSITY   (United States)

^b CELGENE CORPORATION   (United States)

^c Salamandra LLC   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e KAISER PERMANENTE MEDICAL CENTER   (United States)

^f ST MICHAEL S MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; PLACEBO; PROTEINASE INHIBITOR; THALIDOMIDE; TUMOR NECROSIS FACTOR ALPHA; VIRUS RNA;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; AGED; ARTICLE; CALORIC INTAKE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEVER; HUMAN; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NEUTROPHIL; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; VIRUS LOAD; WASTING SYNDROME; WEIGHT GAIN;

ADULT; ANTI-HIV AGENTS; BODY COMPOSITION; BODY WEIGHT; CD4 LYMPHOCYTE COUNT; DOUBLE-BLIND METHOD; ENERGY INTAKE; FEMALE; HIV WASTING SYNDROME; HIV-1; HUMANS; MALE; MIDDLE AGED; THALIDOMIDE; TREATMENT OUTCOME; VIRAL LOAD;

EID: 0034692466     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/08892220050140892     Document Type: Article

References (32)

1. Thalidomide in the treatment of lepra reactions
2. Results of a double blind study of the influence of thalidomide on the lepra reaction
3. Treatment of moderately severe erythema nodosum leprosum with thalidomide - A double blind controlled trial
4. Thalidomide in the treatment of erythema nodosum leprosum
5. An internally-controlled double blind trial of thalidomide in severe erythema nodosum leprosum
6. WHO co-ordinated short-term double-blind trial with thalidomide in the treatment of acute lepra reactions in male lepromatous patients
7. Serum levels of tumor necrosis factor-alpha and interleukin-1β during leprosy reactional states
8. The influence of thalidomide on the clinical and immunologic manifestation of erythema nodosum leprosum
9. Thalidomide treatment reduces tumor necrosis factor a production and enhances weight gain in patients with pulmonary tuberculosis
10. The effect of thalidomide on the pathogenesis of human immunodeficiency virus type 1 and M. tuberculosis infection
11. The metabolic and immunologic effects of short-term thalidomide treatment of patients infected with the human immunodeficiency virus
12. Effects of thalidomide on HIV-associated wasting syndrome: A randomized, double-blind, placebo-controlled clinical trial
13. Prediction of body cell mass, fat-free mass, and total body water with bioelectrical impedance analysis: Effects of race, sex, and disease
14. Size and power of two-sample tests of repeated measures data
15. Thalidomide for the treatment of oral aphthous ulcers in patients with human immunodeficiency virus infection
16. Thalidomide for the treatment of esophageal aphthous ulcers in patients with human immunodeficiency virus infection
17. Thalidomide: A novel therapy for microsporidiosis
18. Thalidomide costimulates primary human T lymphocytes, preferentially inducing proliferation, cytokine production and cytotoxic responses in the CD8+ subset
19. Thalidomide exerts its inhibitory action on tumor necrosis factor by enhancing mRNA degradation
20. Adverse reactions to thalidomide in patients infected with human immunodeficiency virus
21. Thalidomide hypersensitivity in AIDS
22. Polyneuropathy after neurosedyn (thalidomide) and its prognosis
23. Thalidomide neuropathy: A clinical, electrophysiological, and histological follow-up study
24. Dronabinol as a treatment for anorexia associated with weight loss in patients with AIDS
25. Megestrol acetate in patients with AIDS and cachexia
26. Megestrol acetate in patients with AIDS related cachexia
27. Effects of androgen administration in men with the AIDS wasting syndrome
28. Oxandrolone in AIDS-wasting myopathy
29. Resistance exercise and supraphysiologic androgen therapy in eugonadal men with HIV-related weight loss
30. Recombinant human growth hormones in patients with HIV-associated wasting
31. Thalidomide-induced antigen specific immune stimulation in patients with HIV1 and tuberculosis